PuraPharm Corp. Ltd.

As of December 31, 2025, PuraPharm Corp. Ltd. carries a market capitalization of 189.94M, placing it among publicly traded companies globally. Its enterprise value stands at 524.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PuraPharm Corp. Ltd.'s next confirmed earnings release is scheduled for March 31, 2027.

As of December 31, 2025, PuraPharm Corp. Ltd. has 535.05M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, PuraPharm Corp. Ltd. maintains a current ratio of 0.47, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, PuraPharm Corp. Ltd.'s stock has declined approximately 44.00% over the past 52 weeks. The 50-day moving average sits at 0.27, while the 200-day moving average is 0.31.

As of December 31, 2025, PuraPharm Corp. Ltd. holds 16.17M in cash and equivalents against 351.14M in total debt, resulting in a net debt position of 307.65M. Total book value stands at 130.48M, with working capital of -252.33M providing operational flexibility.

PuraPharm Corp. Ltd.'s most recent stock split took place on January 29, 2020 with a 17:18 split ratio.